<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta http-equiv="X-UA-Compatible" content="ie=edge">
  <title>Project VasCura CDE4301</title>
  <link rel="icon" href="./favicon.ico" type="image/x-icon">

  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@shoelace-style/shoelace@2.16.0/cdn/themes/light.css" />
  <script type="module"
    src="https://cdn.jsdelivr.net/npm/@shoelace-style/shoelace@2.16.0/cdn/shoelace-autoloader.js"></script>

  <link rel="stylesheet" href="./index.css">

  <link rel="stylesheet" href="./components/team-member/team-member.css">
  <script type="module" src="./components/team-member/team-member.js"></script>

  <link rel="stylesheet" href="./components/table-of-content/table-of-content.css">

  <script type="module" src="./components/image/image-component.js"></script>

  <script type="module" src="./components/video/video.js"></script>

  <link rel="stylesheet" href="./components/references/references.css">

  <link rel="stylesheet" href="./components/scroll-to-top/scroll-to-top.css">
  <script src="./components/scroll-to-top/scroll-to-top.js"></script>

  <script src="./components/table-component/table-component.js"></script>

  <link href="https://unpkg.com/gridjs/dist/theme/mermaid.min.css" rel="stylesheet" />
  <style>
    #references ol {
      list-style: none;
      counter-reset: ref-counter;
      padding-left: 2em;
    }
    #references ol li {
      counter-increment: ref-counter;
      margin-bottom: 1em;
    }
    #references ol li::before {
      content: "[" counter(ref-counter) "] ";
      margin-right: 0.5em;
    }
  </style>
</head>

<body>
  <div class="layout-wrapper">
    <!-- Fixed Left Sidebar for Table of Contents -->
    <aside class="sidebar">
      <div class="table-of-content">
      <h2>Table of Contents</h2>
      <sl-tree>
        <sl-tree-item>
          <a href="#acknowledgement">Acknowledgement</a>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#list-of-common-acronyms">List of Common Acronyms</a>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#introduction">1. Introduction</a>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#background">2. Background</a>
          <sl-tree-item>
            <a href="#background-of-haemodialysis">2.1. Background of Haemodialysis</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#vascular-access-types">2.2. Vascular Access Types</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#current-standard-of-care">2.3. Current Standard of Care</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#problem-clarification">3. Problem Clarification</a>
          <sl-tree-item>
            <a href="#burden-of-access-failure-and-impact">3.1. Burden of Access Failure </a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#stakeholder-interviews">3.2. Stakeholder Analysis</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#reintervention-reasons">3.3. Reasons for High Re-intervention Rates</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#existing-solutions-and-limitations">3.4. Existing Solutions and Limitations</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#key-insights">3.5. Key Insights</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#need-statement">3.6. Need Statement</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#value-proposition">4. Value Proposition</a>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#design-methodology">5. Design Methodology</a>
          <sl-tree-item>
            <a href="#jobs-to-be-done-pains-and-gains">5.1. Jobs-to-be-Done, Pains and Gains</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#must-haves-and-nice-to-haves">5.2. Must-Haves and Nice-To-Haves</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#initial-functional-analysis">5.3. Initial Functional Analysis</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#design-statement">6. Design Statement</a>
          <sl-tree-item>
            <a href="#design-specifications">6.1. Design Specifications</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#concept-generation">6.2. Concept Generation</a>
            <sl-tree-item>
              <a href="#concept-1">6.2.1 Concept 1</a>
            </sl-tree-item>
            <sl-tree-item>
              <a href="#concept-2">6.2.2 Concept 2</a>
            </sl-tree-item>
            <sl-tree-item>
              <a href="#concept-3">6.2.3 Concept 3</a>
            </sl-tree-item>
            <sl-tree-item>
              <a href="#concept-4">6.2.4 Concept 4</a>
            </sl-tree-item>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#concept-selection">6.3. Concept Selection</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#concept-design">7. Final Concept Design</a>
          <sl-tree-item>
            <a href="#detailed-concept-design">7.1. Detailed Concept Design</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#detailed-conical-shaver-design">7.2. Detailed Conical Shaver Design</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#prototyping">8. Prototyping</a>
          <sl-tree-item>
            <a href="#avf-model">8.1. AVF Model</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#thrombosis-stenosis-analogues">8.2. Thrombosis/Stenosis Analogues</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#prototyping-bench-testing-models">8.3. Blade Design</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#limitations-of-project">9. Limitations and Future Work</a>
          <sl-tree-item>
            <a href="#limitations-of-project">9.1. Limitations of Project</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#future-work">9.2. Future Work</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#conclusion">10. Conclusion</a>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#references">11. References</a>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#appendix">12. Appendix</a>
          <sl-tree-item>
            <a href="#appendix-a">Appendix A - Interview Transcripts</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#appendix-b">Appendix B - Detailed Stakeholder Analysis</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#appendix-c">Appendix C - Detailed Device-Specific Analyses</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#appendix-d">Appendix D - Detailed Concept Generation</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#appendix-e">Appendix E - Pugh Matrix</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#appendix-f">Appendix F - Limitations of Project</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#appendix-g">Appendix G - Additional Prototyping</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#appendix-h">Appendix H - Competition Analysis</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#appendix-i">Appendix I - Singapore Market Analysis</a>
          </sl-tree-item>
        </sl-tree-item>
      </sl-tree>
      </div>
    </aside>

    <!-- Main Content Area (scrolls independently) -->
    <main class="main-content">
      <div class="content">
        <!-- University Logos -->
        <div style="display: flex; justify-content: center; align-items: center; gap: 6em; margin: 0 0 1.5em 0; padding: 1em 0; border-bottom: 2px solid #e5e7eb;">
          <img src="assets/NUS logo.png" alt="NUS Logo" style="max-height: 90px; width: auto; object-fit: contain; filter: drop-shadow(0 2px 4px rgba(0,0,0,0.1)); margin-left: 8cm;">
          <img src="assets/duke nus logo.jpg" alt="Duke-NUS Logo" style="max-height: 90px; width: auto; object-fit: contain; filter: drop-shadow(0 2px 4px rgba(0,0,0,0.1)); margin-right: 7cm; margin-left: -1cm;">
        </div>
        
        <h1 style="margin-top: 1rem;">VasCura</h1>
        <p style="text-align: left; font-size: 1.05rem; font-style: italic; color: #555; margin-top: -10px; margin-bottom: 1rem;">Novel approach to maintain post-intervention AVF patency</p>
        
        <h3 style="text-align: left; margin: 2rem 0 1.5rem 0; font-size: 1.5rem; font-weight: 600; color: var(--text-primary);">Meet the Team</h3>

        <!-- This is the team member component use to display details about your team members -->
        <div class="team-member-wrapper" style="margin: 1rem 0; justify-content: space-around; width: 100%;">
          <team-member class="primary-author" avatar="assets/amelia ong.jpg" name="Amelia Ong" department="NUS Biomedical Engineering"
            year=""></team-member>
          <team-member avatar="assets/lin ming.jpg" name="Lin Ming" department="Duke-NUS Medical School"
            year=""></team-member>
          <team-member avatar="assets/eliot.jpg" name="Dr. Eliot" department="NUS MBA"
            year=""></team-member>
        </div>

        <!-- This is a divide from the shoelace library for aesthetic purpose -->
        <sl-divider style="margin: 1.5rem 0;"></sl-divider>

        <div>

      <!-- Acknowledgement Section -->
      <div id="acknowledgement">
        <h2>Acknowledgement</h2>
        <p>
          I would like to express my sincere gratitude to Professor Mark Chong, my supervisor, for his guidance, encouragement, and invaluable insights throughout this project. I am also deeply grateful to the teaching faculty of Duke-NUS Medical School and the Duke Health Innovator Programme (DHIP) for their continued support in shaping our learning and development.
        </p>
        <p>
          My appreciation extends to Dr. Luke Tay from Singapore General Hospital (SGH), who served as our clinical mentor and provided essential clinical perspective and feedback. I would also like to acknowledge Mr. John as our industry mentor, together with the Becton Dickinson R&D and Innovation team, for their expertise and contributions to the technical aspects of this work.
        </p>
        <p>
          I am thankful as well to Lin Ming, a medical student at Duke-NUS, and Dr. Eliot, whose combined expertise in virology and business enriched the multidisciplinary approach of our team.
        </p>
        <p>
          Finally, I would like to thank the healthcare workers in the Renal Department at SGH for sharing their experiences and perspectives, which greatly informed our understanding of the clinical challenges in Arteriovenous Fistula management.
        </p>
      </div>

      <!-- List of Common Acronyms Section -->
      <div id="list-of-common-acronyms">
        <h2>List of Common Acronyms</h2>
        <p>
        </p>
        <table style="width:100%; border-collapse: collapse; margin-bottom: 2em;">
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">HD</td>
            <td style="border: 1px solid #000; padding: 8px;">Haemodialysis</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">ESKD</td>
            <td style="border: 1px solid #000; padding: 8px;">End-Stage Kidney Disease</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">AVF</td>
            <td style="border: 1px solid #000; padding: 8px;">Arteriovenous Fistula</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">AVG</td>
            <td style="border: 1px solid #000; padding: 8px;">Arteriovenous Graft</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">CVC</td>
            <td style="border: 1px solid #000; padding: 8px;">Central Venous Catheter</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">CC</td>
            <td style="border: 1px solid #000; padding: 8px;">Chronic Clots</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">NIH</td>
            <td style="border: 1px solid #000; padding: 8px;">Neo-intimal Hyperplasia</td>
          </tr>
          <tr>
            <td style="border: 1px solid #000; padding: 8px;">KDOQI</td>
            <td style="border: 1px solid #000; padding: 8px;">Kidney Disease Outcomes Quality Initiative</td>
          </tr>
        </table>
      </div>

      <!-- This is an example of what a section might look like -->
      <div id="introduction">

        <h2> 1. Introduction </h2>
        <p>
          This project, conducted with Singapore General Hospital (Vascular Surgery) and Becton Dickinson, aims to develop a device to restore arteriovenous fistula patency for patients on haemodialysis by addressing the root causes of dialysis access obstruction. This report summarises stakeholder insights, a focused literature review, gaps in current solutions, our concept generation and early prototyping towards a durable, clinically impactful solution.
        </p>
      </div>

      <!-- Background Section -->
      <div id="background">
        <h2>2. Background</h2>
      </div>

      <div id="background-of-haemodialysis">
        <h3>2.1. Background of Haemodialysis</h3>
        <p>
          Haemodialysis (HD) is an extracorporeal therapy that removes metabolic waste, excess salts, and water through a dialyser to maintain chemical balance and blood pressure when kidney function falls below 10–15% [1]. End-stage kidney disease (ESKD) most commonly results from long-term complications of diabetes mellitus and hypertension [2]. During HD, blood is continuously withdrawn through an arterial needle, filtered across a semipermeable membrane, and returned via a venous needle. In Singapore and globally, in-centre HD is performed three times weekly for approximately four hours per session [1].
        </p>

        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/dialysis schematic.jpg" alt="General Schematic of Dialysis" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 1. General Schematic of Dialysis [1]</em></figcaption>
        </figure>
      </div>

      <div id="vascular-access-types">
        <h3>2.2. Vascular Access Types</h3>
        <p>
          To allow safe and sustained blood flow for dialysis, all haemodialysis patients require a surgically created vascular access. This is beacuse native veins are too fragile to handle high flow rates and repeated needle
          insertions, while arteries bleed excessively when punctured directly.
        </p>

        <p>
          The arteriovenous fistula (AVF) artificially connects an artery to a vein, and is the preferred method. Over several weeks,
          arterial pressure remodels and strengthens the vein wall, enabling repeated cannulation and maintaining blood
          flow of 300–500 mL/min for efficient dialysis [3].
        </p>

        <p>
          Other access options, such as arteriovenous grafts (AVG) and central venous catheters (CVC), are used when
          AVF creation is not feasible. AVF remains the gold standard due to its superior long-term patency and lower
          infection rates [4]. In Singapore, approximately 7,000 patients, or 75 percent
          of those on dialysis, rely on an AVF as their primary vascular access [5].
        </p>

        <!-- Figure 2: Arteriovenous Fistula schematic -->
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/AVF.jpg" alt="Schematic of Arteriovenous Fistula" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 2. Schematic of Arteriovenous Fistula [6]</em></figcaption>
        </figure>

        <!-- This is an example of how you might use the image component -->
        <!-- Image 1 (iDP suggested pathway) removed as requested -->
      </div>
    </div>

      <div id="current-standard-of-care">
        <h3>2.3. Current Standard of Care</h3>
        <p>
          Patency refers to the AVF maintaining sufficient luminal diameter and blood flow to support effective dialysis. In constrast, AVF failure is characterised by reduced flow or difficulty with cannulation during dialysis. These signs often indicate stenosis, the abnormal narrowing of a vessel, or thrombosis, the formation of an intraluminal clot that obstructs flow, as outlined in the Kidney Disease Outcomes Quality Initiative (KDOQI) vascular access guidelines [7].
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <!-- Using the requested image file from assets: 'AVF stenosed.jpg' -->
          <img src="assets/AVF stenosed.jpg" alt="AVF stenosed - schematic of stenosis and thrombosis" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 3. Schematic of Stenosis and Thrombosis</em></figcaption>
        </figure>
        <p>
          When this occurs, patients are referred to vascular specialists to restore AVF patency. Although these interventions can re-establish flow, recurrent narrowing and clot formation are common, leading to patients needing multiple interventions over time.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/patient pathway.jpg" alt="Patient pathway - flowchart of AVF patency-restoration pathway" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 4. Flowchart of AVF Patency-Restoration Pathway</em></figcaption>
        </figure>
      </div>

      <div id="problem-clarification">
        <h2>3. Problem Clarification</h2>
      </div>

      <div id="burden-of-access-failure-and-impact">
        <h3>3.1. Burden of Access Failure</h3>
        <p>
          In Singapore, over 9,000 people rely on haemodialysis for survival [8]. Local data show that about two-thirds
          of AVF patients require intervention at some point after their access is created, and
          studies report that one in two patients needs another intervention within six months of the preceding one [9]. Each procedure brings another
          hospital visit, exposure to X-rays, added costs, and discomfort.
        </p>

        <p>
          With Singapore’s ageing population and around 2,000 new kidney-failure cases each year, the demand for access
          maintenance continues to grow. This not only strains healthcare resources but also leads to longer waiting times
          [10].
        </p>

        <p>
          Each AVF salvage intervention costs about SGD 8,000 in direct medical expenses including the operating suite, devices,
          imaging, and sedation, excluding indirect costs such as missed dialysis sessions, transport, and caregiver time
          (Appendix A). Collectively, these represent a substantial financial and emotional burden for both patients and the
          healthcare system.
        </p>
      </div>

      <div id="stakeholder-interviews">
        <h3>3.2. Stakeholder Analysis</h3>
        <p>
          To validate these findings, we interviewed interventional specialists, dialysis nurses, and patients. Their
          insights revealed not only clinical inefficiencies but also user frustrations with current AVF treatments,
          underscoring the urgent need for a durable and workflow-efficient solution. Key stakeholder insights are
          summarised below and detailed in Appendix B.
        </p>

        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px;">Quotes</th>
              <th style="border:1px solid #000; padding:10px;">Problem</th>
              <th style="border:1px solid #000; padding:10px;">Needs</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">"Around 1 in 2 patients require repeat intervention within six months." - Dr Tan</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Frequent loss of patency, resulting in repeated interventions and high long-term treatment burden for patients.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"><strong>Clinicians</strong> require a durable and reliable solution that maintains vessel patency over time to support consistent dialysis access.</td>
            </tr>

            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">“Chronic organised clots remains difficult to clear.” - Dr Alfred, Dr Luke</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Incomplete clearance of chronic clots limits flow restoration and procedural efficiency.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"><strong>Clinicians</strong> require an effective system that safely removes chronic wall-adherent clots.</td>
            </tr>

            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">“~80% of re-interventions are driven by neointimal hyperplasia.” - Dr Apoorva</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">High residual neointimal hyperplasia (NIH) post intervention leads to NIH-driven AVF narrowing.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"><strong>Clinicians</strong> require safe treatment methods that reduce neo-intimal hyperplasia recurrence and preserve vessel wall integrity.</td>
            </tr>

            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">"I had two interventions this year and it is so expensive." - Mdm Tan</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">High financial and emotional burden due to frequent re-interventions.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"><strong>Patients</strong> need a cost-effective and durable solution that reduces repeat interventions and lowers overall treatment cost.</td>
            </tr>

            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">“Sometimes even after intervention, cannulation is still difficult.” - Nurse Aung</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Ineffective clot clearance, leading to poor flow and difficult cannulation for dialysis.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"><strong>Nurses</strong> require a reliable system that restores consistent access flow suitable for dialysis use.</td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:0.5em; font-size:0.95rem;"><em>Table 1. Stakeholder Analysis</em></p>

      </div>

      <div id="reintervention-reasons">
        <h3>3.3. Reasons for High Re-intervention Rates</h3>
        <p>
          We conducted a root cause analysis to understand why AVFs often fail despite repeated intervention to clear the blockage. Two main clusters emerged: factors outside the procedure, such as flow dynamics, patients' comorbidities and vessel condition, and factors within the procedure, primarily the limitations of current devices.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/Root cause analysis.jpg" alt="Root cause analysis table" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 5. Root Cause Analysis</em></figcaption>
        </figure>
        <p>
          Following AVF creation, turbulent haemodynamics and repeated cannulation contribute to the formation of acute clots, chronic clots (CC), and neointimal hyperplasia (NIH) [11]. While acute clots can usually be removed with standard techniques, chronic clot and NIH are dense, fibrotic, and firmly adherent to the vessel wall. 
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/diff clots.jpg" alt="Different clots" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 6. Different clots and NIH</em></figcaption>
        </figure>
        <p>
          A CC becomes firmly attached to the vessel wall over time, composed of cross-linked fibrin, trapped red blood cells, and collagen. This dense, inelastic structure makes it difficult for current devices to remove effectively [12].
        </p>
        <p>
          NIH results from smooth muscle cell proliferation and extracellular matrix buildup triggered by endothelial injury, turbulent flow, and elevated arterial pressures within the AVF circuit. This progressive thickening narrows the vessel lumen and accounts for up to 80% of restenosis cases [13,14] (Appendix A).
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/outflow vein.jpg" alt="Outflow vein - schematic" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 7. Deposition of NIH and CC</em></figcaption>
        </figure>
        <p>
          Together, CC and NIH form tough, wall-adherent lesions that current tools struggle to detach and fully clear, especially in thin, fragile veins. The consequence is residual obstruction, incomplete flow restoration, and a cycle of repeat interventions that ultimately shortens AVF lifespan.
        </p>
      </div>

      <div id="existing-solutions-and-limitations">
        <h3>3.4. Existing Solutions and Limitations</h3>
        
        <p>
          The first-line treatment for a failing AVF typically involves standard balloon angioplasty to restore blood flow. If this is unsuccessful, cutting balloons or drug-coated balloons are used to score the lesion or reduce restenosis. In more severe cases involving clot formation, thrombectomy devices such as rotational, rheolytic, or aspiration systems are employed, while stents are reserved as a last resort.
        A summary of these devices is presented below, with detailed device-specific analyses provided in Appendix C.
        </p>

        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px;">Device Type</th>
              <th style="border:1px solid #000; padding:10px;">Mechanism of Action</th>
              <th style="border:1px solid #000; padding:10px;">Limitations</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Plain Old Balloon Angioplasty [15]</td>
              <td style="border:1px solid #000; padding:10px;">High-pressure inflation compresses clots and NIH against the vessel wall.</td>
              <td style="border:1px solid #000; padding:10px;">Generates radial compression but no shear or cutting force.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Cutting Balloons [16]</td>
              <td style="border:1px solid #000; padding:10px;">Microsurgical blades create controlled incisions in the intima during inflation.</td>
              <td style="border:1px solid #000; padding:10px;">Produces superficial linear cuts with limited penetration depth.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Drug-Coated Balloons [17]</td>
              <td style="border:1px solid #000; padding:10px;">Balloon coated with antiproliferative drugs (e.g., paclitaxel) to reduce NIH regrowth.</td>
              <td style="border:1px solid #000; padding:10px;">Provides chemical inhibition only, lacks mechanical interaction.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Rotational Thrombectomy [18]</td>
              <td style="border:1px solid #000; padding:10px;">Rotating wire or helix mechanically macerates soft clots.</td>
              <td style="border:1px solid #000; padding:10px;">Torque transmission decreases in organised clot but high torque risks venous injury.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Rheolytic Thrombectomy [19]</td>
              <td style="border:1px solid #000; padding:10px;">High-velocity saline jets create a venturi vacuum to fragment and aspirate clots.</td>
              <td style="border:1px solid #000; padding:10px;">Ineffective on dense, adherent lesions and limited shear force.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Aspiration Thrombectomy [20]</td>
              <td style="border:1px solid #000; padding:10px;">Large-bore catheter applies continuous suction to remove clots.</td>
              <td style="border:1px solid #000; padding:10px;">Lacks shearing action to detach adherent material. Limited use in small or tortuous vessels.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Stents [21]</td>
              <td style="border:1px solid #000; padding:10px;">Metal mesh scaffold deployed to prevent recoil and maintain vessel patency.</td>
              <td style="border:1px solid #000; padding:10px;">Prone to fracture or migration under repeated cannulation. Unsuitable for AVF biomechanics.</td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:0.5em; font-size:0.95rem;"><em>Table 2. Current Devices and their Limitations</em></p>

        <p>
          Although existing devices are effective at clearing acute, non-adherent clots, none adequately address wall-adherent lesions such as CC and NIH. As a result, residual burden remains, contributing to early restenosis and repeat interventions.
        </p>
        <p>
          Their limitations fall into two key domains:
        </p>
        <ol style="margin-left:1.5em; padding-left:0;">
          <li style="margin-bottom:0.75em;">
            <strong>Effectiveness:</strong> Limited ability to detach and remove wall-adherent material, often leaving behind residual NIH that seeds rapid recurrence.
          </li>
          <li>
            <strong>Safe Navigation and Deliverability:</strong> Struggle to adapt to thin-walled AVF anatomy, leading to instability and increased risk of wall injury.
          </li>
        </ol>
        <p>
          These gaps highlight the need for a safe, controllable system capable of reliably detaching and evacuating wall-adherent CC and NIH.
        </p>
        <p>
          Using the product positioning map (Fig. 8), which benchmarks VasCura against current treatment modalities, the proposed system directly addresses these unmet needs by mechanically detaching adherent CC and NIH and safely removing liberated material without injuring the fragile vein wall.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/product positioning.jpg" alt="Product positioning map comparing VasCura with existing treatment modalities" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 8. Product Positioning Map</em></figcaption>
        </figure>
      </div>


      <div id="key-insights">
        <h3>3.5. Key Insights</h3>
        <ol style="margin-left:1.5em; padding-left:0;">
          <li style="margin-bottom:1em;">
            Current device actions are <strong>biomechanically mismatched</strong> to AVF lesions. Existing tools rely on compression, low-shear maceration, suction, or drug diffusion, but CC and NIH are anchored within thin-walled, tortuous, low-pressure AVF veins, making them resistant to these mechanisms.
          </li>
          <li style="margin-bottom:1em;">
            Durable patency requires restoring a <strong>≥5 mm</strong> lumen, the KDOQI guideline threshold for achieving adequate dialysis flow. Many current interventions fail to maintain this diameter, leading to early restenosis.
          </li>
          <li>
            Clinician interviews revealed a clear adoption threshold: reducing the <strong>six-month</strong> re-intervention rate from <strong>~50% to ~25%</strong> would represent meaningful durability and justify the use of a new device.
          </li>
        </ol>
      </div>

      <div id="need-statement">
        <h3>3.6. Need Statement</h3>
        <p>
          How might we develop a durable solution that enables clinicians to effectively restore and maintain a <strong>&ge;5&nbsp;mm</strong> luminal diameter in arteriovenous fistula circuits, by removing chronic clots and neointimal hyperplasia, thereby prolonging access patency and reducing the <strong>6-month</strong> reintervention rate from <strong>50% to 25%</strong>?
        </p>
      </div>

      <div id="value-proposition">
        <h2>4. Value Proposition</h2>
        <p><strong>Built for Better Flow — Clears Tough, Navigates Easy, Lasts Longer.</strong></p>
        <p>
          VasCura is the first AVF-specific device engineered to safely remove tough, wall-adherent chronic clot and neointimal hyperplasia while navigating thin-walled, tortuous veins. Its controlled detachment, micro-fragmentation, and debris evacuation mechanism preserves vessel integrity and restores durable flow.
        </p>
      </div>

      <div id="design-methodology">
        <h2>5. Design Methodology</h2>
      </div>

      <div id="jobs-to-be-done-pains-and-gains">
        <h3>5.1. Jobs-to-be-Done, Pains and Gains</h3>
        <p>
          The Jobs-to-be-Done framework identifies the core tasks clinicians must accomplish, along with the associated pains and desired gains. 
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/Jobs to be done.jpg" alt="Jobs-to-be-Done schematic summarising gains, pains, and customer jobs" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 9. Jobs-to-be-Done, Pains and Gains Schematic</em></figcaption>
        </figure>
      </div>

      <div id="must-haves-and-nice-to-haves">
        <h3>5.2. Must-Haves and Nice-To-Haves</h3>
        <p>
        Mapping these elements clarified the performance gaps and defined the must-have requirements for clinical success and the nice-to-have features that improve usability and workflow. These were then translated into quantifiable engineering metrics targeting the drivers of recurrent stenosis.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/Must haves.jpg" alt="Table summarising must-have design requirements" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Table 3. Must-Have Design Requirements</em></figcaption>
        </figure>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/good to have.jpg" alt="Table summarising nice-to-have features and benefits" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Table 4. Nice-To-Have Features</em></figcaption>
        </figure>
      </div>

      <div id="initial-functional-analysis">
        <h3>5.3. Initial Functional Analysis</h3>
        <p>
          An initial functional analysis was conducted to identify the key inputs and outputs of the VasCura system. 
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/black box.jpg" alt="Black box functional model of VasCura system"
            style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 10. Black
              analysis of VasCura system</em></figcaption>
        </figure>
        <p>
          A functional decomposition was then performed to break down the main function of restoring AVF patency into secondary functions, enabling clearer definition and quantification of performance criteria for each stage of the device’s operation.

        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/fucntional decomposition.jpg" alt="Functional decomposition of VasCura system"
            style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 11. Functional decomposition
              of VasCura sub-systems</em></figcaption>
        </figure>
      </div>

      <div id="design-statement">
        <h2>6. Design Statement</h2>
        
      </div>

      <div id="design-specifications">
        <h3>6.1. Design Specifications</h3>
        <p>
          Table 5 summarises the performance requirements for VasCura, mapping each engineering metric to its quantitative target range. These targets are aligned with current clinical standards, the anatomical constraints of AVF segments, and the specifications of complementary devices to ensure integration into existing workflows.
        </p>
        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px;">Requirement</th>
              <th style="border:1px solid #000; padding:10px;">Metric</th>
              <th style="border:1px solid #000; padding:10px;">Target/ Range</th>
              <th style="border:1px solid #000; padding:10px;">Unit</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Clear CC &amp; NIH</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">% residual</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Residual material &lt;30% after
                treatment</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">%</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Maintain patency</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Post-treatment lumen along treated
                length</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">&ge;5.0 mm over &ge;90% of treated
                segment</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">mm</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Be safe for thin AVF walls</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Perforations/dissections</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"> 0
                perforations/dissections (n&ge;10)</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">count</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Deliverable in tortuous veins</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Bend crossing</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Cross 120&deg; bends (radius &ge;10&ndash;15
                mm) [22]</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Degree; pass-fail</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Control debris</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Fraction of liberated mass captured</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">&ge;80% captured/evacuated</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">%</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Compatible with workflow</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Sheath size; guidewire</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">&le;7F, 0.035&quot; (&plusmn;0.018&quot;)
                wire [23]</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">F; in</td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:0.5em; font-size:0.95rem;"><em>Table 5. Design
          Specifications of VasCura</em></p>
      </div>

      <div id="concept-generation">
        <h3>6.2. Concept Generation</h3>
        <p>
          Key solution principles derived from the functional analysis were validated through research and clinician interviews, leading to the development of four concepts. Further details are provided in Appendix D.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/morphological chart.jpg" alt="Morphological Chart" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 12. Morphological Chart </em></figcaption>
        </figure>
      </div>

      <div id="concept-1">
        <h4>6.2.1 Concept 1</h4>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/concept 1.jpg" alt="Concept 1 rendering" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 13. Concept 1 - Dual-Balloon Stabiliser with Rotablade </em></figcaption>
        </figure>
        <p style="margin-top: 1em; text-align: justify;">
          Description: Dual-balloon system enabling stable rotation for clearing wall-adherent NIH and CC, with depth-stop rails to prevent vessel injury.
        </p>
      </div>

      <div id="concept-2">
        <h4>6.2.2 Concept 2</h4>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/concept 2.jpg" alt="Concept 2 rendering" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 14. Concept 2 - Guarded Helical Micro-Shaver </em></figcaption>
        </figure>
        <p style="margin-top: 1em; text-align: justify;">
          Description: Collapsible helical cutter within a wire-guarded casing that shears and removes NIH and CC while preventing vessel trauma and downstream debris migration.
        </p>
      </div>

      <div id="concept-3">
        <h4>6.2.3 Concept 3</h4>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/concept 3.jpg" alt="Concept 3 rendering" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 15. Concept 3 - Tri-Rail Depth-Stop Scoring System </em></figcaption>
        </figure>
        <p style="margin-top: 1em; text-align: justify;">
          Description: Collapsible three-point scoring device that limits vessel penetration, moderately debulks NIH with fewer passes, and captures debris using a distal umbrella net.
        </p>
      </div>

      <div id="concept-4">
        <h4>6.2.4 Concept 4</h4>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/concept 4.jpg" alt="Concept 4 rendering" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 16. Concept 4 - Balloon Guarded Conical Shaver </em></figcaption>
        </figure>
        <p style="margin-top: 1em; text-align: justify;">
          Description: Balloon-assisted conical shaver that safely expands to engage and shear wall-adherent CC and NIH using micro-cutting perforations while preventing direct vessel-wall contact.
        </p>
      </div>

      <div id="concept-selection">
        <h3>6.3. Concept Selection</h3>
        <p>
          We then applied the need criteria and Pugh matrix to systematically evaluate the proposed concepts, allowing us to identify the most feasible and effective design that best meets the clinical and engineering requirements.
        </p>
        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <tr>
            <th colspan="2" style="border:1px solid #000; padding:10px; text-align:left;">Needs criteria evaluation Matrix for concept screening</th>
          </tr>
          <tr>
            <td style="border:1px solid #000; padding:10px; width:70%;">Exceeds criteria</td>
            <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
          </tr>
          <tr>
            <td style="border:1px solid #000; padding:10px;">Meets criteria</td>
            <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
          </tr>
          <tr>
            <td style="border:1px solid #000; padding:10px;">Does not meet criteria</td>
            <td style="border:1px solid #000; padding:10px; text-align:center;">0</td>
          </tr>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:0.5em; font-size:0.95rem;"><em>Table 6. Scoring System for concepts</em></p>
        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px; width:32%;">Needs Criteria (Must Have)</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 1</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 2</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 3</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 4</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Clearance of CC and NIH</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Rate of vessel injury (rupture, dissection) is not higher than existing devices</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Device is within 500–1000 SGD</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Creates a luminal diameter ≥ 5 mm</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Compatibility with existing sheaths and guidewire systems</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;"><strong>Average score</strong></td>
              <td style="border:1px solid #000; padding:10px; text-align:center;"><strong>1.6</strong></td>
              <td style="border:1px solid #000; padding:10px; text-align:center;"><strong>1.8</strong></td>
              <td style="border:1px solid #000; padding:10px; text-align:center;"><strong>1.4</strong></td>
              <td style="border:1px solid #000; padding:10px; text-align:center;"><strong>1.8</strong></td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:0.5em; font-size:0.95rem;"><em>Table 7. Concept ranking using Need Criteria Matrix</em></p>
        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px; width:35%;">Criteria</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 1</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 2</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 3</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 4</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Intellectual Property</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Regulatory</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Business Model</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Technical Feasibility</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;">Need Criteria</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.6</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.8</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.4</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.8</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px;"><strong>Average score</strong></td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.52</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.56</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.48</td>
              <td style="border:1px solid #000; padding:10px; text-align:center; background-color:#d6f5d6;">1.76</td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:0.5em; font-size:0.95rem;"><em>Table 8. Concept ranking using Pugh Matrix (Appendix E)</em></p>
        <p>
          Using this selection method, <strong>Concept 4</strong> was chosen for its balance of feasibility, safety, and innovation.
        </p>
      </div>

      <div id="concept-design">
        <h2>7. Final Concept Design</h2>
      </div>

      <div id="detailed-concept-design">
        <h3>7.1. Detailed Concept Design</h3>
        <p>
          Building on the identified limitations of existing devices, VasCura introduces a novel guarded micro-shearing and capture mechanism that allows complete and safe clearance of adherent NIH and CC.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/pink concept 4.jpg" alt="Finalised Concept Design" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 17. Finalised Concept Design</em></figcaption>
        </figure>
        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px;">Component &amp; Details</th>
              <th style="border:1px solid #000; padding:10px;">Rationale</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">1. Central Guide Wire</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Provides a stable central axis for navigation through tortuous veins. Ensures controlled positioning and advancement within the vessel.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">2. Plain Old Balloon</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">The balloon acts as a safety mechanism by expanding the cone while ensuring its blades never contact the vessel wall due to the built-in offset. It provides uniform, controlled pressure and uses a familiar, clinician-accepted design.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">3. Cheese Grater Blades</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Sharp, low-profile perforations shear CC and NIH and channel debris into the cone, avoiding wall contact and providing a safer alternative to rotating blades.              </td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">4. Cone-shaped Debris Capture</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">The cone geometry enables uniform shear from center to edges, efficiently collecting acute, chronic clots and NIH. Its expandable–collapsible structure allows for smooth retrieval after use.</td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:0.5em; font-size:0.95rem;"><em>Table 9. Detailed Functional Analysis of VasCura</em></p>
        <figure style="margin-top: 1em; text-align: center;">
          <video controls style="max-width:100%; height:auto; background-color:#fff;">
            <source src="assets/final concept 7 demo.mp4" type="video/mp4">
            Your browser does not support the video tag.
          </video>
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Video 1. VasCura Demo</em></figcaption>
        </figure>
      </div>

      <div id="detailed-conical-shaver-design">
        <h3>7.2. Detailed Conical Shaver Design</h3>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/diff clots with our device.jpg" alt="Different clots with device" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 18. VasCura in the vessel</em></figcaption>
        </figure>
        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px;">Design Intent</th>
              <th style="border:1px solid #000; padding:10px;">Rationale</th>
            </tr>
          </thead>
          <tbody>
            <tr>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"> 1. Curvature of blades</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Maintains consistent contact with irregular NIH surfaces, even in tortuous vessel segments.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">2. Sharpness of blades</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">
                Sharp enough to shear fibrotic NIH and CC, but controlled to avoid penetrating the thin AVF vein wall typically <1mm thick. </td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">3. Texture of blades</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Improves grip on fibrotic tissue and channels debris into cone, reducing clogging.

              </td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">4. Distance offset of cone from balloon</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Keeps blades off the vessel wall, balloon expansion limits cone diameter to the intimal layer </td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:0.5em; font-size:0.95rem;"><em>Table 10. Design Considerations of Cheese-Grater-Like Shaver</em></p>
      </div>

      <div id="prototyping">
        <h2>8. Prototyping</h2>

      </div>

      <div id="avf-model">
        <h3>8.1. AVF Model</h3>
        <p>To evaluate the mechanical feasibility of the device concept, we first examined how a physical analogue could be developed to realistically represent the AVF. To address this, a bench-top AVF analogue was developed to replicate the geometry and mechanical properties of native vessels. The model consists of silicone tubing with an internal diameter of 6 mm and an outer diameter of 8 mm, matching the wall thickness and malleability of an actual AVF.</p>
        <div style="display: flex; gap: 1em; margin-top: 1em; justify-content: center; flex-wrap: wrap; align-items: stretch;">
          <figure style="flex: 1; min-width: 300px; max-width: 48%; text-align: center; margin: 0; display: flex; flex-direction: column;">
            <div style="width: 100%; height: 400px; display: flex; align-items: center; justify-content: center; border: 1px solid #ddd; padding: 4px; background: #fff; box-sizing: border-box;">
              <img src="assets/entire circuit clear.jpg" alt="Patent AVF circuit" style="max-width: 100%; max-height: 100%; width: auto; height: auto; object-fit: contain;" />
            </div>
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 19. Patent AVF circuit</em></figcaption>
          </figure>
          <figure style="flex: 1; min-width: 300px; max-width: 48%; text-align: center; margin: 0; display: flex; flex-direction: column;">
            <div style="width: 100%; height: 400px; display: flex; align-items: center; justify-content: center; border: 1px solid #ddd; padding: 4px; background: #fff; box-sizing: border-box;">
              <img src="assets/entire circuit not clear.jpg" alt="Blocked AVF circuit" style="max-width: 100%; max-height: 100%; width: auto; height: auto; object-fit: contain;" />
            </div>
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 20. Blocked AVF circuit</em></figcaption>
          </figure>
        </div>
      </div>

      <div id="thrombosis-stenosis-analogues">
        <h3>8.2. Thrombosis/Stenosis Analogues</h3>
        <p>A threefold scaled-up version was also fabricated to facilitate visualisation and testing. Silicone sealant was applied to reproduce the texture and toughness of NIH, while dusty blue Blu-Tack was used to simulate CC. The design and material selection were validated with clinicians to ensure representative tactile and structural realism. To enhance physiological accuracy, development is underway for a 3D-printed polyjet vessel model incorporating variable silicone mixtures to simulate layered NIH tissue.</p>
        <div style="display: flex; gap: 1em; margin-top: 1em; justify-content: center; flex-wrap: wrap; align-items: stretch;">
          <figure style="flex: 1; min-width: 300px; max-width: 48%; text-align: center; margin: 0; display: flex; flex-direction: column;">
            <div style="width: 100%; height: 400px; display: flex; align-items: center; justify-content: center; border: 1px solid #ddd; padding: 4px; background: #fff; box-sizing: border-box;">
              <img src="assets/6mm patent.jpg" alt="6mm patent AVF" style="max-width: 100%; max-height: 100%; width: auto; height: auto; object-fit: contain;" />
            </div>
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 21. 6mm Patent Silicone Tubing</em></figcaption>
          </figure>
          <figure style="flex: 1; min-width: 300px; max-width: 48%; text-align: center; margin: 0; display: flex; flex-direction: column;">
            <div style="width: 100%; height: 400px; display: flex; align-items: center; justify-content: center; border: 1px solid #ddd; padding: 4px; background: #fff; box-sizing: border-box;">
              <img src="assets/6mm not patent.jpg" alt="6mm not patent AVF" style="max-width: 100%; max-height: 100%; width: auto; height: auto; object-fit: contain;" />
            </div>
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 22. 6mm Not Patent Silicone Tubing</em></figcaption>
          </figure>
        </div>
        <div style="display: flex; gap: 1em; margin-top: 1em; justify-content: center; flex-wrap: wrap; align-items: stretch;">
          <figure style="flex: 1; min-width: 300px; max-width: 48%; text-align: center; margin: 0; display: flex; flex-direction: column;">
            <div style="width: 100%; height: 400px; display: flex; align-items: center; justify-content: center; border: 1px solid #ddd; padding: 4px; background: #fff; box-sizing: border-box;">
              <img src="assets/patent 20,,.jpg" alt="20mm patent silicone tubing" style="max-width: 100%; max-height: 100%; width: auto; height: auto; object-fit: contain;" />
            </div>
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 23. 20mm Patent Silicone Tubing</em></figcaption>
          </figure>
          <figure style="flex: 1; min-width: 300px; max-width: 48%; text-align: center; margin: 0; display: flex; flex-direction: column;">
            <div style="width: 100%; height: 400px; display: flex; align-items: center; justify-content: center; border: 1px solid #ddd; padding: 4px; background: #fff; box-sizing: border-box;">
              <img src="assets/blocked 20mm.jpg" alt="20mm not patent silicone tubing" style="max-width: 100%; max-height: 100%; width: auto; height: auto; object-fit: contain;" />
            </div>
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 24. 20mm Not Patent Silicone Tubing</em></figcaption>
          </figure>
        </div>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/blue tack 20mm.jpg" alt="20mm chronic clot silicone tubing" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 25. 20mm Chronic Clot Silicone Tubing</em></figcaption>
        </figure>
      </div>

      <div id="prototyping-bench-testing-models">
        <h3>8.3. Blade Design</h3>
        <p>To assess cutting performance, a functional prototype was built using a bent cheese grater micro-shearing surface mounted on a Foley catheter with an enlarged Fogarty-type balloon. The prototype was scaled to a threefold vessel model to evaluate its ability to remove CC and NIH. Different blade shapes, sizes, and sharpness levels are being tested to determine which configuration provides effective lesion removal while preserving vessel wall integrity. NIH reduction will be quantified using ImageJ to measure the extent of material removed with initial tests showing strong cutting potential.</p>
        <div style="display: flex; gap: 1em; margin-top: 1em; justify-content: center; flex-wrap: wrap; align-items: stretch;">
          <figure style="flex: 1; min-width: 300px; max-width: 48%; text-align: center; margin: 0; display: flex; flex-direction: column;">
            <div style="width: 100%; height: 400px; display: flex; align-items: center; justify-content: center; border: 1px solid #ddd; padding: 4px; background: #fff; box-sizing: border-box;">
              <img src="assets/cheese grater long.jpg" alt="Testing of blades" style="max-width: 100%; max-height: 100%; width: auto; height: auto; object-fit: contain;" />
            </div>
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 26. Testing of blades</em></figcaption>
          </figure>
          <figure style="flex: 1; min-width: 300px; max-width: 48%; text-align: center; margin: 0; display: flex; flex-direction: column;">
            <div style="width: 100%; height: 400px; display: flex; align-items: center; justify-content: center; border: 1px solid #ddd; padding: 4px; background: #fff; box-sizing: border-box;">
              <img src="assets/Final look like prorotype.jpg" alt="Final look-like prototype" style="max-width: 100%; max-height: 100%; width: auto; height: auto; object-fit: contain;" />
            </div>
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 27. Final look-like prototype</em></figcaption>
          </figure>
        </div>
        <p>
        </p>
        <div style="display: flex; gap: 1em; margin-top: 1em; justify-content: center; flex-wrap: wrap; align-items: stretch;">
          <figure style="flex: 1; min-width: 300px; max-width: 48%; text-align: center; margin: 0; display: flex; flex-direction: column;">
            <img src="assets/Image J analysis.png" alt="Image J analysis" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 28. Image J analysis</em></figcaption>
          </figure>
          <figure style="flex: 1; min-width: 300px; max-width: 48%; text-align: center; margin: 0; display: flex; flex-direction: column;">
            <img src="assets/blade results.jpg" alt="Blade results" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 29. Blade results</em></figcaption>
          </figure>
        </div>
      </div>

      <div id="limitations-of-project">
        <h2>9. Limitations and Future Work</h2>
        <h3>9.1. Limitations</h3>
        <p>
          Progress is currently limited by two main issues that guide the next steps of development. First, the vein and NIH analogues do not yet fully match the mechanical behaviour of fibrotic lesions, which affects the accuracy of bench-top testing. Second, the conical shaver’s behaviour in tortuous AVF anatomy has not yet been evaluated, so its interaction with vessel bends remains to be characterised. Moving forward, we will refine the lesion models and test the device in vessels of varying curvatures, including a bi-directional “flossing” cutting approach. Further points are outlined in Appendix F.
        </p>
      </div>

      <div id="future-work">
        <h3>9.2. Future Work</h3>
        <p>
          Future prototyping has been structured into four development phases. Phase 0 focuses on finalising the bench-top vessel model for testing. Phase 1 involves the fabrication of the functional cutting element, followed by Phase 2, which covers the design of the deployment mechanism. Phase 3 integrates the balloon and cutting components into a unified system, while the final phase will include comprehensive validation of the complete prototype, targeted for completion by Dazzle Day.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/prototype plan.jpg" alt="Prototype plan showing development phases" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure 30. Prototype development plan</em></figcaption>
        </figure>
        <p>
          Each prototyping phase will include a specific testing plan, with consistent overall metrics used to evaluate performance across iterations in table 11.
        </p>
        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px;">Category</th>
              <th style="border:1px solid #000; padding:10px;">Details</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"><strong>End Point</strong></td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Achieve and maintain a ≥ 5 mm lumen diameter across a 10 cm treated length.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"><strong>Metrics</strong></td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">
                <ul style="margin:0; padding-left:1.5em;">
                  <li>Lumen diameter (pre/post): measured via ImageJ</li>
                  <li>% Residual material</li>
                  <li>Wall injury: visual + dye-leak inspection</li>
                  <li>Debris capture (%): collected vs. total released</li>
                  <li>Operation time (minutes)</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"><strong>Sample Size</strong></td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">n = 5 per lesion grade (50%, 70%, 80% stenosis)</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;"><strong>Acceptance Criteria</strong></td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">
                <ul style="margin:0; padding-left:1.5em;">
                  <li>≤ 30% residual material</li>
                  <li>No vessel perforation</li>
                  <li>≥ 80% debris captured</li>
                  <li>≤ 5 minutes per trial</li>
                </ul>
              </td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:0.5em; font-size:0.95rem;"><em>Table 11. Testing plan specifications</em></p>
      </div>

      <div id="conclusion">
        <h2>10. Conclusion</h2>
        <p>
          This work clarified the unmet need for sustained AVF patency and developed a vein-safe, mechanically focused concept to address the chronic lesions that drive recurrent stenosis. Grounded in clinical requirements and user insights, the design establishes a credible foundation for reducing re-intervention rates. Future prototyping and validation will determine its readiness for clinical translation.
        </p>
      </div>

    <!-- This is an example of how you can use the references component to create references -->
    <div id="references" class="references">
      <h2>11. References</h2>
      <ol>
        <li style="margin-bottom: 1em;">
          National Kidney Foundation, "Hemodialysis," <em>National Kidney Foundation</em>, Apr. 26, 2024. 
          https://www.kidney.org/kidney-topics/hemodialysis 
          (accessed Nov. 01, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          P. Rout and A. Aslam, "End-Stage Renal Disease," <em>National Library of Medicine</em>, Jun. 22, 2025. 
          https://www.ncbi.nlm.nih.gov/books/NBK499861/ 
          (accessed Nov. 01, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          C. E. Lok et al., "KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update," <em>American Journal of Kidney Diseases</em>, vol. 75, no. 4, pp. S1–S164, Apr. 2020, 
          doi: https://doi.org/10.1053/j.ajkd.2019.12.001.
        </li>
        <li style="margin-bottom: 1em;">
          National Institute of Diabetes and Digestive and Kidney Diseases, "Hemodialysis," <em>National Institute of Diabetes and Digestive and Kidney Diseases</em>, Jan. 2018. 
          https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis 
          (accessed Nov. 01, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          S. C. Pang et al., "Current state of vascular access in Singapore," <em>The Journal of Vascular Access</em>, vol. 21, no. 5, pp. 582–588, Sep. 2019, 
          doi: https://doi.org/10.1177/1129729819878595.
        </li>
        <li style="margin-bottom: 1em;">
          "Arteriovenous fistula formation &amp; dialysis - Dr Jill O'Donnell," <em>Dr Jill O'Donnell</em>, Feb. 13, 2023. 
          https://drjillodonnell.com.au/patient-resources/arteriovenous-fistula-formation-dialysis/ 
          (accessed Nov. 01, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          National Kidney Foundation, "NKF KDOQI clinical practice guidelines," <em>National Kidney Foundation</em>, Aug. 12, 2024. 
          https://www.kidney.org/professionals/kdoqi
        </li>
        <li style="margin-bottom: 1em;">
          "Key Statistics – The National Kidney Foundation (NKF) Singapore," <em>nkfs.org</em>. 
          https://nkfs.org/about-us/key-statistics/ 
          (accessed Nov. 02, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          R. Y. Tan et al., "Outcomes of endovascular salvage of clotted arteriovenous access and predictors of patency after thrombectomy," <em>Journal of Vascular Surgery</em>, vol. 71, no. 4, pp. 1333–1339, Sep. 2019, 
          doi: https://doi.org/10.1016/j.jvs.2019.07.056.
        </li>
        <li style="margin-bottom: 1em;">
          "Annual Reports – The National Kidney Foundation (NKF) Singapore," <em>nkfs.org</em>. 
          https://nkfs.org/about-us/annual-reports/ 
          (accessed Nov. 02, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          M. M. Engelen, P. Verhamme, and T. Vanassche, "Clotting of the Extracorporeal Circuit in Hemodialysis: Beyond Contact-Activated Coagulation," <em>Seminars in Nephrology</em>, vol. 43, no. 6, pp. 151473–151473, Nov. 2023, 
          doi: https://doi.org/10.1016/j.semnephrol.2023.151473.
        </li>
        <li style="margin-bottom: 1em;">
          M. A. Zain, R. T. Jamil, and W. J. Siddiqui, "Neointimal Hyperplasia," <em>PubMed</em>, 2021. 
          https://www.ncbi.nlm.nih.gov/books/NBK499893/
        </li>
        <li style="margin-bottom: 1em;">
          S. Srakocic, "Understanding Chronic Thrombosis," <em>Healthline</em>, Sep. 08, 2023. 
          https://www.healthline.com/health/chronic-thrombosis
        </li>
        <li style="margin-bottom: 1em;">
          N. Wilson John, C. Dang, N. Reddy, C. Chao, K. J. Ho, and B. Jiang, "Bioengineering Strategies for Treating Neointimal Hyperplasia in Peripheral Vasculature: Innovations and Challenges," <em>Advanced Healthcare Materials</em>, vol. 14, no. 7, Jan. 2025, 
          doi: https://doi.org/10.1002/adhm.202401056.
        </li>
        <li style="margin-bottom: 1em;">
          "Mustang Balloon Dilatation Catheter," <em>www.bostonscientific.com</em>, 2025. 
          https://www.bostonscientific.com/en-US/products/catheters--balloon/Mustang_Balloon_Dilatation_Catheter.html 
          (accessed Nov. 02, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          "Peripheral Cutting BalloonTM Microsurgical Dilatation Device for Hemodialysis Access Management," <em>www.bostonscientific.com</em>, 2025. 
          https://www.bostonscientific.com/en-US/products/catheters--balloon/peripheral-cutting-balloon.html 
          (accessed Nov. 02, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          "AGENTTM Drug-Coated Balloon (DCB) - Boston Scientific," <em>Boston Scientific</em>, 2024. 
          https://www.bostonscientific.com/us/en/healthcare-professionals/products/balloons-catheters-and-guidewires/drug-coated-balloons/agent-drug-coated-balloon/fp00000400.html 
          (accessed Nov. 13, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          "CLEANERTM Rotational Thrombectomy System | Argon Medical Devices," <em>Argon Medical Devices</em>, Jul. 08, 2024. 
          https://www.argonmedical.com/product/cleaner-rotational-thrombectomy-system-cleaner-rotational-thrombectomy-system/ 
          (accessed Nov. 02, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          "AngioJetTM Peripheral Thrombectomy System," <em>Boston Scientific</em>, 2015. 
          https://www.bostonscientific.com/us/en/healthcare-professionals/products/thrombectomy-systems/angiojet-peripheral-thrombectomy-system/fp90000109.html 
          (accessed Nov. 02, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          "Penumbra System | Penumbra Inc," <em>Penumbra, Inc</em>, May 30, 2023. 
          https://www.penumbrainc.com/products/penumbra-system/ 
          (accessed Nov. 02, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          "BD CoveraTM Vascular Covered Stent – Precision for AV Access Management | BD," <em>Bd.com</em>, 2023. 
          https://www.bd.com/en-sea/products-and-solutions/products/product-families/covera-vascular-covered-stent 
          (accessed Nov. 02, 2025).
        </li>
        <li style="margin-bottom: 1em;">
          X. Li, C. Liu, and H. Hu, "Prevailing insights into anastomotic angles of surgically created arteriovenous fistulas: a literature review," <em>BMC Nephrology</em>, vol. 26, no. 1, pp. 252–252, May 2025, 
          doi: https://doi.org/10.1186/s12882-025-04182-4.
        </li>
        <li style="margin-bottom: 1em;">
          D. Mazzaccaro, M. Giannetta, Paolo Righini, A. Modafferi, G. Malacrida, and G. Nano, "Endovascular Materials and Their Behavior in Peripheral Vascular Surgery," <em>Frontiers in Surgery</em>, vol. 9, May 2022, 
          doi: https://doi.org/10.3389/fsurg.2022.900364.
        </li>
      </ol>
    </div>

    <!-- Appendix Section -->
    <div id="appendix">
      <h2>12. Appendix</h2>
      <p>
        Additional supporting information and detailed analyses are provided in the following appendices:
      </p>
      <ul style="margin-left: 1.5em; padding-left: 0;">
        <li style="margin-bottom: 0.75em;">
          <strong>Appendix A:</strong> Interview transcripts
        </li>
        <li style="margin-bottom: 0.75em;">
          <strong>Appendix B:</strong> Detailed stakeholder insights
        </li>
        <li style="margin-bottom: 0.75em;">
          <strong>Appendix C:</strong> Detailed device-specific analyses
        </li>
        <li style="margin-bottom: 0.75em;">
          <strong>Appendix D:</strong> Detailed concept generation information
        </li>
        <li style="margin-bottom: 0.75em;">
          <strong>Appendix E:</strong> Pugh Matrix and detailed rationale
        </li>
        <li style="margin-bottom: 0.75em;">
          <strong>Appendix F:</strong> Limitations of Project 
        </li>
        <li style="margin-bottom: 0.75em;">
          <strong>Appendix G:</strong> Additional Prototyping
        </li>
        <li style="margin-bottom: 0.75em;">
          <strong>Appendix H:</strong> Competition Analysis
        </li>
        <li style="margin-bottom: 0.75em;">
          <strong>Appendix I:</strong> Singapore Market Analysis
        </li>
      </ul>

      <div id="appendix-a">
        <h3>Appendix A - Interview Transcripts</h3>
        <p>
          We conducted 40 interviews with stakeholders including interventional radiologists, renal physicians, dialysis nurses, and patients. The key interviews that provided the most significant insights are highlighted in this section.
        </p>
        
        <div style="margin-bottom: 2em;">
          <h4 style="margin-top: 1.5em; margin-bottom: 0.5em; font-weight: 600;">Interview 1: Mdm Tan, Dialysis Patient (SGH Dialysis Centre)</h4>
          <p style="margin: 0.25em 0;"><strong>Date:</strong> 20 Aug</p>
          <p style="margin: 0.25em 0;"><strong>Mode:</strong> In-person</p>
          <p style="margin-top: 0.75em; margin-bottom: 0.5em;"><strong>Key Points:</strong></p>
          <ul style="margin-left: 1.5em; padding-left: 0;">
            <li style="margin-bottom: 0.5em;">Underwent two interventions in the past year for reduced AVF flow.</li>
            <li style="margin-bottom: 0.5em;">Aware of bleeding risks but unclear about pulmonary embolism (PE) risks.</li>
            <li style="margin-bottom: 0.5em;">No major concerns about thrombectomy and had no complications afterward.</li>
            <li style="margin-bottom: 0.5em;">High cost is a major concern — first balloon angioplasty was SGD 8,000.</li>
            <li style="margin-bottom: 0.5em;">Reports many fellow patients experiencing repeated interventions to restore patency.</li>
          </ul>
        </div>

        <div style="margin-bottom: 2em;">
          <h4 style="margin-top: 1.5em; margin-bottom: 0.5em; font-weight: 600;">Interview 2: Dr. Milo, Renal Physician (SGH Renal Department)</h4>
          <p style="margin: 0.25em 0;"><strong>Date:</strong> 22 Aug</p>
          <p style="margin: 0.25em 0;"><strong>Mode:</strong> In-person</p>
          <p style="margin-top: 0.75em; margin-bottom: 0.5em;"><strong>Key Points:</strong></p>
          <ul style="margin-left: 1.5em; padding-left: 0;">
            <li style="margin-bottom: 0.5em;">Challenges: long procedure time in thrombosed aneurysmal AVFs; bleeding risks.</li>
            <li style="margin-bottom: 0.5em;">PE extremely rare (0.1%, 1 in 1000 cases yearly).</li>
            <li style="margin-bottom: 0.5em;">Follow-up pattern: 1/3 return every 3 months, 1/3 yearly, 1/3 never return.</li>
            <li style="margin-bottom: 0.5em;">Thrombus clearance has 80–90% technical success, but patency loss rates are high—</li>
            <li style="margin-bottom: 0.5em; margin-left: 1em;">50% of AVG lose patency by 3 months</li>
            <li style="margin-bottom: 0.5em; margin-left: 1em;">50% of AVF lose patency by 6 months</li>
          </ul>
        </div>

        <div style="margin-bottom: 2em;">
          <h4 style="margin-top: 1.5em; margin-bottom: 0.5em; font-weight: 600;">Interview 3: Mr. Aung, Renal Nurse (RHS Dialysis Centre)</h4>
          <p style="margin: 0.25em 0;"><strong>Date:</strong> 26 Aug</p>
          <p style="margin: 0.25em 0;"><strong>Mode:</strong> In-person</p>
          <p style="margin-top: 0.75em; margin-bottom: 0.5em;"><strong>Key Points:</strong></p>
          <ul style="margin-left: 1.5em; padding-left: 0;">
            <li style="margin-bottom: 0.5em;">Difficult cannulation in endoAVFs (weak thrill) and pre-emptive AVFs (deep veins).</li>
            <li style="margin-bottom: 0.5em;">Some patients require angioplasty every ~2 months.</li>
            <li style="margin-bottom: 0.5em;">Access flow affected by cannulation technique and patient factors.</li>
            <li style="margin-bottom: 0.5em;">Variation in referral thresholds for low-flow AVFs across different centres.</li>
            <li style="margin-bottom: 0.5em;">Ladder technique increases lifespan but patients often request same-site cannulation.</li>
            <li style="margin-bottom: 0.5em;">Buttonhole technique avoided due to hygiene/infection risk.</li>
            <li style="margin-bottom: 0.5em;">Transonic flow-monitoring device is expensive ($50k + high maintenance).</li>
            <li style="margin-bottom: 0.5em;">Arterial pressure-based flow monitoring is less accurate.</li>
          </ul>
        </div>

        <div style="margin-bottom: 2em;">
          <h4 style="margin-top: 1.5em; margin-bottom: 0.5em; font-weight: 600;">Interview 4: Dr. Apoorva, Interventional Radiologist (SGH IR)</h4>
          <p style="margin: 0.25em 0;"><strong>Date:</strong> 26 Aug</p>
          <p style="margin: 0.25em 0;"><strong>Mode:</strong> WhatsApp</p>
          <p style="margin-top: 0.75em; margin-bottom: 0.5em;"><strong>Key Points:</strong></p>
          <ul style="margin-left: 1.5em; padding-left: 0;">
            <li style="margin-bottom: 0.5em;">Thrombosis/stenosis occurs in ~20% of dialysis circuits.</li>
            <li style="margin-bottom: 0.5em;">Challenges: long procedure time, radiation exposure, patient pain, high costs, recurrence.</li>
            <li style="margin-bottom: 0.5em;">Complication rate around 10%.</li>
            <li style="margin-bottom: 0.5em;">PE is a theoretical risk but clinically insignificant in his 15+ years of practice.</li>
            <li style="margin-bottom: 0.5em;">Cost reduction not essential — benefit must justify cost for adoption.</li>
          </ul>
        </div>

        <div style="margin-bottom: 2em;">
          <h4 style="margin-top: 1.5em; margin-bottom: 0.5em; font-weight: 600;">Interview 5: Dr. Alfred, Interventional Radiologist (SGH IR)</h4>
          <p style="margin: 0.25em 0;"><strong>Date:</strong> 25 Aug</p>
          <p style="margin: 0.25em 0;"><strong>Mode:</strong> Email</p>
          <p style="margin-top: 0.75em; margin-bottom: 0.5em;"><strong>Key Points:</strong></p>
          <ul style="margin-left: 1.5em; padding-left: 0;">
            <li style="margin-bottom: 0.5em;">Challenges: long procedures, difficulty clearing chronic clot/large aneurysmal burdens.</li>
            <li style="margin-bottom: 0.5em;">Key concerns: ability to treat the culprit lesion and balloon selection, both affecting patency.</li>
            <li style="margin-bottom: 0.5em;">Residual debris occurs in ~10% of cases; sometimes causes early issues.</li>
            <li style="margin-bottom: 0.5em;">PE rarely observed; long-term impact unknown.</li>
            <li style="margin-bottom: 0.5em;">Procedures last 1–2.5 hours; 30 min reduction is meaningful.</li>
            <li style="margin-bottom: 0.5em;">Patency of 9–12 months would be significant.</li>
          </ul>
        </div>

        <div style="margin-bottom: 2em;">
          <h4 style="margin-top: 1.5em; margin-bottom: 0.5em; font-weight: 600;">Interview 6: Dr. Alvin, Renal Physician (SGH Renal)</h4>
          <p style="margin: 0.25em 0;"><strong>Date:</strong> 28 Aug</p>
          <p style="margin: 0.25em 0;"><strong>Mode:</strong> In-person</p>
          <p style="margin-top: 0.75em; margin-bottom: 0.5em;"><strong>Key Points:</strong></p>
          <ul style="margin-left: 1.5em; padding-left: 0;">
            <li style="margin-bottom: 0.5em;">Clinically significant PE is rare (~twice a year).</li>
            <li style="margin-bottom: 0.5em;">Difficulties with pain management, aneurysmal AVFs, lower success in complex cases.</li>
            <li style="margin-bottom: 0.5em;">Recurrence often due to residual clot or recurrent stenosis.</li>
            <li style="margin-bottom: 0.5em;">Emphasised equal importance of wall scraping and debris capture.</li>
            <li style="margin-bottom: 0.5em;">Patency loss is multifactorial, influenced by patient BP and vessel biology.</li>
          </ul>
        </div>

        <div style="margin-bottom: 2em;">
          <h4 style="margin-top: 1.5em; margin-bottom: 0.5em; font-weight: 600;">Interview 7: Dr. Milo (Follow-up), Renal Physician (SGH Renal)</h4>
          <p style="margin: 0.25em 0;"><strong>Date:</strong> 4 Sept</p>
          <p style="margin: 0.25em 0;"><strong>Mode:</strong> WhatsApp</p>
          <p style="margin-top: 0.75em; margin-bottom: 0.5em;"><strong>Key Points:</strong></p>
          <ul style="margin-left: 1.5em; padding-left: 0;">
            <li style="margin-bottom: 0.5em;">~80% of culprit lesions are NIH; remainder due to fibrosis or scarring.</li>
            <li style="margin-bottom: 0.5em;">Significant stenosis = >50% narrowing.</li>
            <li style="margin-bottom: 0.5em;">Adequate POBA outcome = <30% residual stenosis.</li>
            <li style="margin-bottom: 0.5em;">Success measured either technically or clinically (flow-based).</li>
            <li style="margin-bottom: 0.5em;">Suggested using flow rate, not lumen diameter, for clinical success.</li>
            <li style="margin-bottom: 0.5em;">Consider operator time, effort, radiation exposure.</li>
          </ul>
        </div>

        <div style="margin-bottom: 2em;">
          <h4 style="margin-top: 1.5em; margin-bottom: 0.5em; font-weight: 600;">Interview 8: Dr. Apoorva (Follow-up), IR (SGH)</h4>
          <p style="margin: 0.25em 0;"><strong>Date:</strong> 4 Sept</p>
          <p style="margin: 0.25em 0;"><strong>Mode:</strong> WhatsApp</p>
          <p style="margin-top: 0.75em; margin-bottom: 0.5em;"><strong>Key Points:</strong></p>
          <ul style="margin-left: 1.5em; padding-left: 0;">
            <li style="margin-bottom: 0.5em;">80% NIH-driven; some surgical scarring.</li>
            <li style="margin-bottom: 0.5em;">Target flow: >800 mL/min (minimum acceptable: >600 mL/min).</li>
            <li style="margin-bottom: 0.5em;">If target lesion revascularisation <30% at 12 months, it is a major improvement.</li>
          </ul>
        </div>

        <div style="margin-bottom: 2em;">
          <h4 style="margin-top: 1.5em; margin-bottom: 0.5em; font-weight: 600;">Interview 9: Dr. Pang Suh Chien, Renal Physician (SGH)</h4>
          <p style="margin: 0.25em 0;"><strong>Date:</strong> 3 Oct</p>
          <p style="margin: 0.25em 0;"><strong>Mode:</strong> In-person</p>
          <p style="margin-top: 0.75em; margin-bottom: 0.5em;"><strong>Key Points:</strong></p>
          <ul style="margin-left: 1.5em; padding-left: 0;">
            <li style="margin-bottom: 0.5em;">Cutting balloons inefficient: needed multiple passes for 20 cm stenosis.</li>
            <li style="margin-bottom: 0.5em;">First-line: POBA → cutting balloon → DCB → thrombectomy.</li>
            <li style="margin-bottom: 0.5em;">Notes Penumbra is expensive.</li>
          </ul>
        </div>
      </div>

      <div id="appendix-b">
        <h3>Appendix B - Detailed Stakeholder Analysis</h3>
        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px;">Quotes</th>
              <th style="border:1px solid #000; padding:10px;">Problem</th>
              <th style="border:1px solid #000; padding:10px;">Needs</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">"Around 1 in 2 patients require repeat intervention within six months, showing the limited durability of current AVF treatments." - Dr Tan (Interventional Nephrologist)</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Frequent loss of patency, resulting in repeated interventions and high long-term treatment burden for patients.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Clinicians require a durable and reliable solution that maintains vessel patency over time to support consistent dialysis access.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">"Chronic organised thrombus remains difficult to clear effectively with existing devices." - Dr Alfred (Interventional Radiologist), Dr Luke (Vascular Surgeon)</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Incomplete clearance of chronic thrombus limits flow restoration and procedural efficiency.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Operators require an effective system that safely removes chronic wall-adherent thrombus.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">"Approximately 80% of re-interventions are driven by neointimal hyperplasia, highlighting its major role in AVF failure." - Dr Apoorva (Interventional Radiology)</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">High residual neointimal hyperplasia (NIH) post intervention leads to NIH-driven restenosis.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Clinicians require safe treatment method that reduces intimal hyperplasia recurrence and preserves vessel wall integrity.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">"I have been through my 2nd interventions in the past year and it is so expensive." - Mdm Tan (Patient)</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">High financial and emotional burden due to frequent re-interventions.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Patients need a cost-effective and durable solution that reduces repeat interventions and lowers overall treatment cost.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">"Sometimes even after intervention, I find it hard to cannulate the AVF" - Nurse Aung (Nurse)</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Ineffective thrombus clearance, leading to poor flow and difficult cannulation for dialysis.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Clinicians require a reliable system that restores consistent access flow suitable for dialysis use.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">"Managing long venous segments with short balloons is inefficient and time-consuming." - Dr Pang (Interventional Nephrologist)</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Device-handling inefficiency during treatment of long or tortuous venous segments.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Operators require a flexible, ergonomic system for efficient treatment of long, tortuous venous segments.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">"Complex procedures are lengthy and expose both patient and operator to high radiation." - Dr Alvin (Interventional Nephrologist)</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Extended procedure times and radiation exposure increase risk and fatigue.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Clinicians require a workflow-efficient solution that enables faster lumen restoration.</td>
            </tr>
          </tbody>
        </table>
      </div>

      <div id="appendix-c">
        <h3>Appendix C - Detailed Device-Specific Analyses</h3>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/detailed devices pt 1.jpg" alt="Detailed Device Analysis Part 1" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure C1. Detailed Device Analysis Part 1</em></figcaption>
        </figure>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/detailed devices pt 2.jpg" alt="Detailed Device Analysis Part 2" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure C2. Detailed Device Analysis Part 2</em></figcaption>
        </figure>
      </div>

      <div id="appendix-e">
        <h3>Appendix E - Pugh Matrix</h3>
        <p>
          The Pugh Matrix was used to systematically evaluate the four concepts across multiple criteria including intellectual property, regulatory considerations, business model, technical feasibility, and need criteria. The complete matrix with rationale is presented below.
        </p>
        <table style="width:100%; border-collapse: collapse; margin: 1.5em 0;">
          <thead style="background-color:#f2f2f2; text-align:left;">
            <tr>
              <th style="border:1px solid #000; padding:10px; width:35%;">Criteria</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 1</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 2</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 3</th>
              <th style="border:1px solid #000; padding:10px; text-align:center;">Concept 4</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:1px solid #000; padding:10px; font-weight:bold;">Intellectual Property</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; font-style:italic; padding-left:2em;">Rationale</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Currently no innovation on double balloon system</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Currently no innovation on guarding and a helical shaver</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">One company working on tri rail depth stop scoring system</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Currently no innovation on conical shaver mounted on balloon</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; font-weight:bold;">Regulatory</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; font-style:italic; padding-left:2em;">Rationale</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Likely Class II device requiring 510(k) clearance.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Likely Class II device requiring 510(k) clearance.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Likely Class II device requiring 510(k) clearance.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Likely Class II device requiring 510(k) clearance.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; font-weight:bold;">Business Model/Payment</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; font-style:italic; padding-left:2em;">Rationale</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Single-use, sheath-delivered device fits existing AVF reimbursement models; low capital required.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Same disposable model, compatible with standard workflow.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Similar cost/usage structure; no capital console.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Similar single-use balloon pricing model.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; font-weight:bold;">Technical Feasibility</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">2</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; font-style:italic; padding-left:2em;">Rationale</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Mechanically complex: independent rotation of blade while balloon remains fixed so sheath redesign needed.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Feasible: helical cutter inside guarded casing is mechanically simpler to prototype.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Straightforward: fixed rails with scoring edges with low mechanical risk.</td>
              <td style="border:1px solid #000; padding:10px; vertical-align:top;">Feasible: balloon is off shelf and conical cutter is simpler to prototype.</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; font-weight:bold;">Need Criteria</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.6</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.8</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.4</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.8</td>
            </tr>
            <tr>
              <td style="border:1px solid #000; padding:10px; font-weight:bold;">Average score</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.52</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.56</td>
              <td style="border:1px solid #000; padding:10px; text-align:center;">1.48</td>
              <td style="border:1px solid #000; padding:10px; text-align:center; background-color:#d6f5d6;">1.76</td>
            </tr>
          </tbody>
        </table>
        <p style="text-align:center; font-style:italic; color:#333; margin-top:0.5em; font-size:0.95rem;"><em>Table E1. Complete Pugh Matrix with Rationale</em></p>
      </div>

      <div id="appendix-f">
        <h3>Appendix F - Limitations of Project</h3>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/limitations part 1.jpg" alt="Limitations Part 1" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure F1. Limitations Part 1</em></figcaption>
        </figure>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/limitations part 2.jpg" alt="Limitations Part 2" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure F2. Limitations Part 2</em></figcaption>
        </figure>
      </div>

      <div id="appendix-g">
        <h3>Appendix G - Additional Prototyping</h3>
        <p>
          To determine how best to shape the micro-shearing cutting elements in Concept 4, we first built look- and feel-like prototypes to understand their mechanical behaviour. Early iterations used helical, hexagonal, and mesh stainless-steel wires as depth-stopping rails, which were tested in silicone vessel models with clinician feedback. However, these rail-based designs struggled to engage deeper layers of CC and NIH, and sharpening them only increased the risk of vein-wall injury. In parallel, preliminary prototypes of Concepts 1 and 2 showed that multi-component, independently controlled mechanisms were complex to operate and inefficient at detaching NIH. These insights led us to simplify the system: using the balloon itself to limit cutting depth and mounting a cone-shaped, cheese-grater–like shearing surface on top. This cone-on-balloon configuration provided better lesion contact, smoother cutting, and a safer, more effective approach for removing CC and NIH.
        </p>
        <div style="display: flex; flex-wrap: wrap; gap: 1em; margin-top: 1em; justify-content: center;">
          <figure style="flex: 1 1 calc(33.333% - 1em); min-width: 200px; text-align: center; margin: 0;">
            <img src="assets/wires.jpg" alt="Wires prototype" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure G1. Wires prototype</em></figcaption>
          </figure>
          <figure style="flex: 1 1 calc(33.333% - 1em); min-width: 200px; text-align: center; margin: 0;">
            <img src="assets/wires in tube.jpg" alt="Wires in tube prototype" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure G2. Wires in tube prototype</em></figcaption>
          </figure>
          <figure style="flex: 1 1 calc(33.333% - 1em); min-width: 200px; text-align: center; margin: 0;">
            <img src="assets/dr luke w wires.jpg" alt="Dr. Luke with wires prototype" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure G3. Dr. Luke with wires prototype</em></figcaption>
          </figure>
          <figure style="flex: 1 1 calc(33.333% - 1em); min-width: 200px; text-align: center; margin: 0;">
            <img src="assets/concept 1 look like.jpg" alt="Concept 1 look-like prototype" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure G4. Concept 1 look-like prototype</em></figcaption>
          </figure>
          <figure style="flex: 1 1 calc(33.333% - 1em); min-width: 200px; text-align: center; margin: 0;">
            <img src="assets/concept 2 look like.jpg" alt="Concept 2 look-like prototype" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
            <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure G5. Concept 2 look-like prototype</em></figcaption>
          </figure>
        </div>
      </div>

      <div id="appendix-h">
        <h3>Appendix H - Competition Analysis</h3>
        <p>
          We analysed the procedure volumes at SGH and mapped out how frequently each device is used, as well as how well they perform against key clinical needs.
        </p>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/Competition Analysis Pt 1.jpg" alt="Competition Analysis Part 1" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure H1. Competition Analysis Part 1</em></figcaption>
        </figure>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/Competition Analysis pt2.jpg" alt="Competition Analysis Part 2" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure H2. Competition Analysis Part 2</em></figcaption>
        </figure>
      </div>

      <div id="appendix-i">
        <h3>Appendix I - Singapore Market Analysis</h3>
        <figure style="margin-top: 1em; text-align: center;">
          <img src="assets/Singapore Market Analysis.jpg" alt="Singapore Market Analysis" style="max-width:100%; height:auto; border: 1px solid #ddd; padding:4px; background:#fff;" />
          <figcaption style="font-size:0.95rem; color:#333; margin-top:0.5em;"><em>Figure I1. Singapore Market Analysis</em></figcaption>
        </figure>
      </div>
    </div>

    </div>
    </main>
  </div>

  <!-- This is the code to display the scroll to top button for ergonomic -->
  <!-- You can leave it as it is, or if you don't like its aesthetics you can also just delete it, -->
  <!-- but it might reduce the user experience. -->
  <sl-button class="scroll-to-top" variant="primary" size="medium" circle onclick="scrollToTop()">
    <sl-icon name="arrow-up" label="Settings"></sl-icon>
  </sl-button>

  <script src="https://unpkg.com/gridjs/dist/gridjs.umd.js"></script>
  <script type="module" src="./components/table-component/table-component.js"></script>
</body>

</html>
